Acute liver and kidney injury caused by orlistat capsules
10.3760/cma.j.cn114015-20220119-00058
- VernacularTitle:奥利司他胶囊致急性肝损伤和肾损伤
- Author:
Chen LI
1
;
Haibin SU
1
;
Jinhua HU
1
;
Chenhui SHI
1
Author Information
1. 解放军总医院第五医学中心肝病医学部肝病科，北京 100039
- Publication Type:Journal Article
- Keywords:
Anti-obesity agents;
Chemical and drug induced liver injury;
Drug-related side effect and adverse reactions;
Orlistat
- From:
Adverse Drug Reactions Journal
2022;24(9):502-504
- CountryChina
- Language:Chinese
-
Abstract:
A 37-year-old female patient took orlistat capsules 120 mg thrice daily orally for weight loss. Four weeks later, she developed fatigue, poor appetite, and nausea; 6 weeks later, jaundice and decreased urine volume occurred and laboratory tests showed alanine aminotransferase (ALT) 7 631 U/L, aspartate aminotransferase (AST) 6 295 U/L, total bilirubin (TBil) 46.0 μmol/L, serum creatinine (Scr) 266 μmol/L, and international normalized ratio (INR) 1.73. Acute liver and kidney injury caused by orlistat capsules was considered. Then orlistat was discontinued, and symptomatic and supportive treatments such as liver protection, enzyme lowering, fluid replacement, and renal perfusion improvement were given. Ten days later, the symptoms above-mentioned in the patient were improved obviously, and laboratory tests showed ALT 181 U/L, AST 25 U/L, TBil 9.8 μmol/L, Scr 121 μmol/L, and INR 0.9. The liver and renal function in the patient was normal both at 3 months and 1 year of follow-up.
